Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing

Novartis reported positive early results for its lead CAR-T candidate CTL019 in DLBCL that appear to be consistent with Kite's competing therapy in the same indication, but the data show the Swiss big pharma ran into manufacturing issues that weren't resolved until later in the JULIET study.